Auxiliary liver transplantation for subfulminant iproniazid-related hepatitis. Should iproniazid still be sold in France ?;Transplantation hépatique auxiliaire pour hépatite subfulminante à l'iproniazide. Doit-on maintenir la commercialisation de l'iproniazide en France ?

Gastroenterologie Clinique et Biologique

Volumn 23, Issue 10, 1999, Pages 1083-1085

  Maille, François ^a   Duvoux, Christophe ^a   Cherqui, Daniel ^a   Radier, Catherine ^a   Zafrani, Elie Serge ^a   Dhumeaux, Daniel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

Auto antibodies; Auxiliary graft; Hepatotoxicity; Iproniazid; Liver transplantation; Subfulminant hepatitis

Indexed keywords

ANTIDEPRESSANT AGENT; IMMUNOSUPPRESSIVE AGENT; IPRONIAZID; MONOAMINE OXIDASE INHIBITOR;

ADULT; ARTICLE; FEMALE; FOLLOW UP; HUMAN; LIVER TRANSPLANTATION; MALE; TIME; TOXIC HEPATITIS;

ADULT; ANTIDEPRESSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IPRONIAZID; LIVER TRANSPLANTATION; MALE; MONOAMINE OXIDASE INHIBITORS; TIME FACTORS;

EID: 0033203489     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure : definition and causes. Semin Liver Dis 1986;6:97-106.
2. Larrey D. Hépatites aiguës médicamenteuses : imputabilité et aspects cliniques. Gastrocnterol Clin Biol 1995;19 : B57-62.
3. Danan G. Définition et critères d'imputation des atteintes hépatiques aiguës médicamenteuses. Conclusions d'une réunion internationale de consensus. Gastroenterol Clin Biol 1993;17 : H18-21.
4. Homberg JC, Stelly M, Andreis I, Abuaf N, Saadoun F, André J. A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis. Clin Exp Immunol 1982;47:93-103.
5. Danan G, Homberg JC, Bernuau J, Roche-Sicot J, Pessayre D. Hépatite à l'iproniazide : intérêt diagnostique d'un nouvel anticorps antimitochondrial, l'anti-M6. Gastrocnterol Clin Biol 1983;7:529-32.
6. Lefebure B, Castot A, Danan G, Elmalem J, Jean-Pastor MJ, Efthymiou ML. Hépatites aux antidépresseurs. Bilan des observations de l'association française des centres de pharmacovigilance et de la commission technique. Thérapie 1984;39:509-16.
7. Rosenblum LE, Korn RJ, Zimmerman HJ. Hepatocellular jaundice as a complication of iproniazid therapy. Arch Intern Med 1960;105:583-93.
8. Pons C, Dansette PM, Gregeois J, Homberg JC, Billett EE, Mansuy D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Biochem Biophys Res Commun 1996;218:118-24.
9. O'Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of proanosis in fulminant hepatic failure. Gastroenterology 1989;97:439-45.
10. Bismuth H, Samuel D, Gugenheim J, Castaing D, Bernuau J, Rueff B, et al. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med 1987;107:337-41.
11. Bemuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognosis factors in fulminant hepatitis B. Hepatology 1986;6:648-51.
12. Chenard-Neu MP, Boudjema K, Bernuau J, Degott C, Belghiti J, Cherqui D, et al. Auxiliary liver transplantation : regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure. A multicenter European study. Hepatology 1996;23:1119-27.
13. Moritz MJ, Jarell BE, Armenti V, Radomski J, Carabasi RA, Zeitoun G, et al. Heterotopic liver transplantation for fulminant hepatic failure : a bridse to recovery. Transplantation 1990;50:524-6.
14. Belghiti J, Zinzindohoue F, Durand F, Noun R, Sauvanet A, Bemuau J. Auxiliary liver transplantation for fulminant liver failure : limits of an attractive concept (abstract). Hepatology 1995;22:153A.